Engage Bio

Durable genetic medicine, redosable

Santa Clara, California, US

A biotech startup developing mRNA immunotherapies to eliminate cancer. Their Tethosomes platform uses LNP technology to deliver DNA/mRNA, turning cancer cells into localized immunotherapy factories.

Shareable draft

Check out Engage Bio on @MedStartr Today A biotech startup developing mRNA immunotherapies to eliminate cancer. Their Tethosomes platform uses LNP technology to deliver DNA/mRNA, turning cancer cells into localized immunotherapy factories. #SolidTumors #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/A9OQJ-7oz_c

Get Involved in Engage Bio

How We Help

Problem Statement

Delivering potent, durable, and scalable genetic medicine for solid tumors with minimized toxicity and immune evasion.

Core Technology

Tethosomes

Key Differentiators

Tethosomes platform turns cancer cells into immunotherapy factories; Localizes DNA to the nucleus for increased expression while evading immune sensors; A new class of non-viral DNA medicine for localized treatment

Clinical Focus

Oncology

Company Info

Business Model: Hybrid
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: engage.bio

Disease Areas

Solid Tumors Cancer & Oncology

Technologies

ImmunotherapyGene TherapyLNPLipid NanoparticleNon-Viral DeliveryTethosomesmRNA Technology

Clinical & IP

🔬

Clinical Validation

Platform advancing toward first human clinical programs. Gates Foundation grant awarded for non-viral DNA delivery technology. Y Combinator-backed (2022 seed: $500K).

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Engage Bio?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.